Moteur de recherche d’entreprises européennes
Financement de l’UE (5 982 255 €) : Théranostique de nouvelle génération des pathologies cérébrales avec des nanoréseaux autonomes contrôlables de l’extérieur : une approche transdisciplinaire avec … Hor01/01/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Théranostique de nouvelle génération des pathologies cérébrales avec des nanoréseaux autonomes contrôlables de l’extérieur : une approche transdisciplinaire avec des interfaces bio-nanodispositifs
Brain pathologies are highly complex disorders. Despite recent progress, their prognosis is grim, defining a high societal challenge. Bridging life sciences, bio-nanotechnology, engineering and ICT, GLADIATOR promises a vanguard and comprehensive theranostic (therapeutic+diagnostic) solution for brain malignancies. Through a multi-faceted breakthrough, GLADIATOR will provide, for the first time, a working prototype of a complete, autonomous and clinically applicable, nanonetwork-based, Molecular Communications system based on the conceptual framework of Externally Controllable Molecular Communications (ECMC). Using Glioblastoma Multiforme tumours, the most detrimental brain pathologies, as a proof-of-concept case, GLADIATOR will implement a platform of cell-based and electronic components. Implantable autologous organoids of engineered neural stem cells (iNSCs) will release rationally designed exosomal bio-nanomachines, delivering reprogramming (therapeutic) miRNAs and building nanonetworks. Interfering with the underlying biological environment, the nanonetworks will define a revolutionary intervention. A hybrid bio-electronic interface, consisting of coupled external and implantable devices, will enable communication channels with host-derived fluorescent bio-nanomachines via micro-optoelectronic sensors. The cellular, sub-cellular and electronic components will be integrated into a wireless ECMC network. This system will autonomously monitor the spatiotemporal tumour evolution and recurrence and generate, on demand, appropriate reprogramming interventions, by radiofrequency stimulation of iNSC renewal. A paradigm shift in Oncology Research is anticipated via the supra-discipline of “bio-nanomachine diagnostics”. GLADIATOR establishes a radical long-term vision leading to a drastic change in cancer therapy, also ushering the emergence of the ECMC field and transforming the burgeoning industry of Internet of Nano-bio-things, with high socioeconomic impact.
| E.P.O.S. Iasis Research and Development Ltd. | 1 111 540 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 1 758 104 € |
| Norges Teknisk-Naturvitenskapelige Universitet Ntnu | 787 076 € |
| OULUN YLIOPISTO | 950 535 € |
| South East Technological University | 421 875 € |
| THE University OF Osaka | 0,00 € |
| University of Cyprus | 953 125 € |
https://cordis.europa.eu/project/id/828837
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.